---
schema_version: "secwatch.filing_event.v1"
accession: "0001607062-21-000349"
form_type: "8-K"
ticker: "RGBP"
cik: "0001589150"
company_name: "Regen BioPharma Inc"
filed_at: "2021-09-24T23:59:59+00:00"
generated_at: "2026-06-29T01:32:45.036181+00:00"
event_type: "debt"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Regen Biopharma secures $1.39M net financing via $1.5M note, settles ChemDiv lawsuit for $800K

## Summary
- Issued $1.5M promissory note to Coventry Enterprises LLC; net proceeds $1.39M after $75K OID and $35K fees.
- Note carries 5% guaranteed interest, matures July 2022, convertible only upon default.
- Paid $800K to ChemDiv to settle lawsuit; settlement includes release of claims and protects IP.
- CEO David Koos reports progress: current SEC filings, $1.905M licensing revenue in Q2 2021, revived patents.
- Goals include settling all convertible notes, hiring CSO, and seeking OTCQB listing.

## SEC filing metadata
- accession: 0001607062-21-000349
- form_type: 8-K
- ticker: RGBP
- cik: 0001589150
- company_name: Regen BioPharma Inc
- filed_at: 2021-09-24T23:59:59+00:00
- event_type: debt
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1589150/000160706221000349/0001607062-21-000349-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1589150/000160706221000349/rgbp092421form8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001607062-21-000349
- JSON: https://secwatch.observer/filing/0001607062-21-000349.json
- Plain text: https://secwatch.observer/filing/0001607062-21-000349.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.